Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 1/20 | 0.40 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.40 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.40 |
| ▸ | IDO1 | P14902 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | CFTR | P13569 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | ATM | Q13315 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11441775 | 0.86 | SLC6A2 (0.43) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL21316578 | 0.80 | IDO1 (0.53) | SLC6A4IDO1CYP3A4CYP2D6 | |
| SCHEMBL1261721 | 0.79 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL8369193 | 0.79 | ALDH1A1 (0.46) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL3556000 | 0.77 | IDO1 (0.44) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL20472319 | 0.76 | HRH4 (0.46) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL7669263 | 0.76 | ALDH1A1 (0.44) | SLC6A2SLC6A4SLC6A3ALDH1A1KDM4E | |
| SCHEMBL14899798 | 0.76 | ALDH1A1 (0.45) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL27969183 | 0.76 | IDO1 (0.43) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 | |
| SCHEMBL8320254 | 0.76 | IDO1 (0.43) | SLC6A2SLC6A4SLC6A3IDO1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082793-A1 | Methods of ortho alkylation | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-04-29 | — | — | US | claimed |
| EP-1368310-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. du Pont de Nemours and Company (US) | 2003-12-10 | — | — | EP | claimed |
| WO-2002072540-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-09-19 | — | — | WO | claimed |
| EP-2059502-A2 | PROLINE UREA CCR1 ANTAGONISTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR INFLAMMATION | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-05-20 | — | — | EP | disclosed |
| EP-1700845-B1 | Insecticidal anthranilamides | DU PONT (US) | 2008-12-10 | — | — | EP | disclosed |
| US-7338978-B2 | Insecticidal anthranilamides | E.I. DU PONT DE NEMOURS AND COMPANY (US) | 2008-03-04 | — | — | US | disclosed |
| WO-2008011392-A2 | PROLINE UREA CCR1 ANTAGONISTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR INFLAMMATION | LIGAND PHARMACUETICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| WO-2008011392-A2 | PROLINE UREA CCR1 ANTAGONISTS FOR THE TREATMENT OF AUTOIMMUNE DISEASES OR INFLAMMATION | LIGAND PHARMACUETICALS INCORPORATED (US) | 2008-01-24 | — | — | WO | disclosed |
| EP-1265850-B1 | INSECTICIDAL ANTHRANILAMIDES | DU PONT (US) | 2007-01-03 | — | — | EP | disclosed |
| US-7145035-B2 | Methods of ortho alkylation | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1700845-A1 | Insecticidal anthranilamides | E.I.Du pont de nemours and company (US) | 2006-09-13 | — | — | EP | disclosed |
| US-6747047-B2 | ARTHROPODICIDES | E.I. DU PONT DE NEMOURS AND COMPANY | 2004-06-08 | — | — | US | disclosed |
| US-20040082793-A1 | Methods of ortho alkylation | E. I. DU PONT DE NEMOURS AND COMPANY | 2004-04-29 | — | — | US | disclosed |
| US-20030229050-A1 | Insecticidal anthranilamides | FMC CORPORATION | 2003-12-11 | — | — | US | disclosed |
| EP-1368310-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. du Pont de Nemours and Company (US) | 2003-12-10 | — | — | EP | disclosed |
| EP-1341772-A2 | QUINAZOLINONES AND PYRIDINYLPYRIMIDINONES FOR CONTROLLING INVERTEBRATE PESTS | E. I. du Pont de Nemours and Company (US) | 2003-09-10 | — | — | EP | disclosed |
| WO-2002072540-A2 | IMPROVED METHODS OF ORTHO ALKYLATION | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-09-19 | — | — | WO | disclosed |
| WO-2002048115-A2 | QUINAZOLINONES AND PYRIDINOPYRIMIDINONES FOR CONTROLLING INVERTEBRATE PESTS | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2002-06-20 | — | — | WO | disclosed |
| US-4031227-A | CNS DEPRESSANT AGENTS, SLEEP INDUCERS, TRANQUILIZERS | SANDOZ, INC. (US) | 1977-06-21 | — | — | US | disclosed |
| US-4006183-A | CNS DEPRESSANT | SANDOZ, INC. (US) | 1977-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030229050-A1 | Insecticidal anthranilamides | ANTXR2, NIT2, CYB5R3 | SLC6A2 4274/4885SLC6A4 4604/4885SLC6A3 4709/4885 |
| US-20040082793-A1 | Methods of ortho alkylation | CBR1, AOC2, CBR3 | SLC6A2 3046/4885SLC6A4 4171/4885SLC6A3 2587/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.